Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis
Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic c...
Saved in:
| Published in | The Journal of immunology (1950) Vol. 181; no. 11; pp. 7948 - 7957 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Am Assoc Immnol
01.12.2008
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-1767 1550-6606 1550-6606 |
| DOI | 10.4049/jimmunol.181.11.7948 |
Cover
| Abstract | Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-γ recall responses using PBMCs from healthy subjects previously exposed to Mtb. From this screen, dominant human T cell Ags were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis. Eighteen of the individual Ags conferred partial protection against challenge with virulent Mtb. A combination of three of these Ags further increased protection against Mtb to levels comparable to those achieved with bacillus Calmette-Guérin vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge-induced pluripotent CD4 and CD8 T cells, including Th1 cell responses characterized by elevated levels of Ag-specific IgG2c, IFN-γ, and TNF. Priority vaccine Ags elicited pluripotent CD4 and CD8 T responses in purified protein derivative-positive donor PBMCs. This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis. |
|---|---|
| AbstractList | Development of a subunit vaccine for
Mycobacterium tuberculosis
(
Mtb
) depends on the identification of antigens that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94
Mtb
genes based on criteria which included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-γ recall responses using PBMC from healthy subjects previously exposed to
Mtb
. From this screen, dominant human T-cell antigens were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis (TB). Eighteen of the individual antigens conferred partial protection against challenge with virulent
Mtb
. A combination of three of these antigens further increased protection against
Mtb
to levels comparable to those achieved with BCG vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge induced pluripotent CD4 and CD8 T cells, including T
H
1 cell responses characterized by elevated levels of antigen-specific IgG2c, IFN-γ and TNF. Priority vaccine antigens elicited pluripotent CD4 and CD8 T responses in PPD
+
donor PBMC. This study identified numerous novel human T cell antigens suitable to be included in subunit vaccines against TB. Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-gamma recall responses using PBMCs from healthy subjects previously exposed to Mtb. From this screen, dominant human T cell Ags were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis. Eighteen of the individual Ags conferred partial protection against challenge with virulent Mtb. A combination of three of these Ags further increased protection against Mtb to levels comparable to those achieved with bacillus Calmette-Guérin vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge-induced pluripotent CD4 and CD8 T cells, including Th1 cell responses characterized by elevated levels of Ag-specific IgG2c, IFN-gamma, and TNF. Priority vaccine Ags elicited pluripotent CD4 and CD8 T responses in purified protein derivative-positive donor PBMCs. This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis.Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-gamma recall responses using PBMCs from healthy subjects previously exposed to Mtb. From this screen, dominant human T cell Ags were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis. Eighteen of the individual Ags conferred partial protection against challenge with virulent Mtb. A combination of three of these Ags further increased protection against Mtb to levels comparable to those achieved with bacillus Calmette-Guérin vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge-induced pluripotent CD4 and CD8 T cells, including Th1 cell responses characterized by elevated levels of Ag-specific IgG2c, IFN-gamma, and TNF. Priority vaccine Ags elicited pluripotent CD4 and CD8 T responses in purified protein derivative-positive donor PBMCs. This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis. Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-γ recall responses using PBMCs from healthy subjects previously exposed to Mtb. From this screen, dominant human T cell Ags were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis. Eighteen of the individual Ags conferred partial protection against challenge with virulent Mtb. A combination of three of these Ags further increased protection against Mtb to levels comparable to those achieved with bacillus Calmette-Guérin vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge-induced pluripotent CD4 and CD8 T cells, including Th1 cell responses characterized by elevated levels of Ag-specific IgG2c, IFN-γ, and TNF. Priority vaccine Ags elicited pluripotent CD4 and CD8 T responses in purified protein derivative-positive donor PBMCs. This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis. Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-gamma recall responses using PBMCs from healthy subjects previously exposed to Mtb. From this screen, dominant human T cell Ags were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis. Eighteen of the individual Ags conferred partial protection against challenge with virulent Mtb. A combination of three of these Ags further increased protection against Mtb to levels comparable to those achieved with bacillus Calmette-Guérin vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge-induced pluripotent CD4 and CD8 T cells, including Th1 cell responses characterized by elevated levels of Ag-specific IgG2c, IFN-gamma, and TNF. Priority vaccine Ags elicited pluripotent CD4 and CD8 T responses in purified protein derivative-positive donor PBMCs. This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis. |
| Author | Coler, Rhea N Bertholet, Sylvie Guderian, Jeffrey Mohamath, Raodoh Laughlin, Elsa M Ireton, Gregory C Baldwin, Susan L Stride, Nicole Reed, Steven G Kahn, Maria Vedvick, Thomas S |
| Author_xml | – sequence: 1 fullname: Bertholet, Sylvie – sequence: 2 fullname: Ireton, Gregory C – sequence: 3 fullname: Kahn, Maria – sequence: 4 fullname: Guderian, Jeffrey – sequence: 5 fullname: Mohamath, Raodoh – sequence: 6 fullname: Stride, Nicole – sequence: 7 fullname: Laughlin, Elsa M – sequence: 8 fullname: Baldwin, Susan L – sequence: 9 fullname: Vedvick, Thomas S – sequence: 10 fullname: Coler, Rhea N – sequence: 11 fullname: Reed, Steven G |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19017986$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxS1URLeFb4CQT4hLlrGTOAkHpGr500pFXApXy3Emu1459mI7XfXb42XbqnDgNIf5vTej987IifMOCXnNYFlB1b3fmmmanbdL1rIlY8umq9pnZMHqGgohQJyQBQDnBWtEc0rOYtwCgABevSCnrAPWdK1YkO3VgC6Z0WiVjHfUj_RynpSjN3SF1tKLvFyji3T0gaYN0k94i9bvpqw6wD-V1sZhpGqtjIuJfrvTvlc6YTDzRNPcY9Cz9dHEl-T5qGzEV_fznPz48vlmdVlcf_96tbq4LnTFRSrEOOiu7loceFu2LRs6rKtSCQ68Ay5E0_dirGuEAVhXgYK-RSzFoBgKVjZQnpOPR9_d3E846PxpUFbugplUuJNeGfn3xpmNXPtbyetW5FCywdt7g-B_zRiTnEzUOQ3l0M9RZojxqm4y-ObppccTD_Fm4MMR0MHHGHCU2qQ_QefDxkoG8tClfOhS5i4lY_LQZRZX_4gf_f8ve3eUbcx6szcBZZyUtflFJvf7_VP0NwRStfs |
| CitedBy_id | crossref_primary_10_1002_pro_4892 crossref_primary_10_1074_mcp_M112_018846 crossref_primary_10_1002_jcb_23449 crossref_primary_10_1111_j_1365_3083_2012_02726_x crossref_primary_10_2147_IJN_S364634 crossref_primary_10_1128_CVI_00482_12 crossref_primary_10_1016_j_coi_2015_06_001 crossref_primary_10_1073_pnas_1314973111 crossref_primary_10_3390_cells12020317 crossref_primary_10_1016_j_vaccine_2009_06_093 crossref_primary_10_3389_fimmu_2023_1127515 crossref_primary_10_1038_gt_2011_140 crossref_primary_10_1038_srep37793 crossref_primary_10_3389_fmicb_2021_763289 crossref_primary_10_1016_j_meegid_2020_104186 crossref_primary_10_1126_scitranslmed_3001094 crossref_primary_10_1371_journal_ppat_1003130 crossref_primary_10_1016_j_vaccine_2021_07_002 crossref_primary_10_3389_fimmu_2021_695278 crossref_primary_10_3389_ftubr_2023_1303505 crossref_primary_10_3390_vaccines11010130 crossref_primary_10_1016_S2213_2600_20_30319_2 crossref_primary_10_1016_j_aller_2020_05_002 crossref_primary_10_1093_infdis_jiv055 crossref_primary_10_1371_journal_pone_0083884 crossref_primary_10_1038_s41598_023_39578_5 crossref_primary_10_1371_journal_pone_0022074 crossref_primary_10_1016_j_tube_2021_102054 crossref_primary_10_1038_s41541_018_0057_5 crossref_primary_10_1080_21645515_2020_1818522 crossref_primary_10_1093_femspd_fty039 crossref_primary_10_3389_fimmu_2019_02806 crossref_primary_10_4049_jimmunol_1301161 crossref_primary_10_1074_mcp_M113_032623 crossref_primary_10_1038_icb_2009_14 crossref_primary_10_1128_CVI_00458_15 crossref_primary_10_1016_j_vaccine_2011_06_029 crossref_primary_10_1016_j_jconrel_2013_12_025 crossref_primary_10_1096_fj_202002537RR crossref_primary_10_1371_journal_pone_0071351 crossref_primary_10_1016_j_ijmyco_2013_10_004 crossref_primary_10_1016_j_vaccine_2011_07_094 crossref_primary_10_1128_spectrum_01066_23 crossref_primary_10_1111_jcmm_12867 crossref_primary_10_3389_fimmu_2025_1430808 crossref_primary_10_1002_jcb_27872 crossref_primary_10_1038_s41541_024_00834_y crossref_primary_10_3389_fimmu_2018_00310 crossref_primary_10_1007_s00894_025_06301_2 crossref_primary_10_2147_IDR_S300162 crossref_primary_10_1111_mmi_14409 crossref_primary_10_1038_s41598_021_88291_8 crossref_primary_10_1038_s41598_019_39402_z crossref_primary_10_1111_j_1365_3083_2010_02444_x crossref_primary_10_1111_jcmm_13965 crossref_primary_10_1016_j_tube_2015_03_001 crossref_primary_10_1128_microbiolspec_BAI_0024_2019 crossref_primary_10_1016_j_vaccine_2009_10_063 crossref_primary_10_1016_j_tube_2014_12_009 crossref_primary_10_1016_j_imbio_2015_11_006 crossref_primary_10_1186_s43556_024_00243_6 crossref_primary_10_1371_journal_pone_0016333 crossref_primary_10_1016_j_tube_2014_06_004 crossref_primary_10_3389_fimmu_2023_1110843 crossref_primary_10_1016_j_coi_2009_05_017 crossref_primary_10_1128_CVI_00198_10 crossref_primary_10_1186_s41479_016_0020_z crossref_primary_10_1016_j_cimid_2015_11_002 crossref_primary_10_1016_j_vaccine_2013_07_032 crossref_primary_10_1186_1471_2334_14_179 crossref_primary_10_1371_journal_ppat_1007139 crossref_primary_10_3389_fimmu_2024_1441944 crossref_primary_10_1208_s12249_021_02146_z crossref_primary_10_7759_cureus_51955 crossref_primary_10_3390_vaccines10122127 crossref_primary_10_1371_journal_pone_0143552 crossref_primary_10_3389_ftubr_2024_1435344 crossref_primary_10_1016_j_actatropica_2021_106035 crossref_primary_10_3389_fimmu_2020_557809 crossref_primary_10_1007_s00005_010_0068_z crossref_primary_10_1021_acsomega_0c04774 crossref_primary_10_1096_fj_11_199588 crossref_primary_10_3389_fimmu_2022_878471 crossref_primary_10_1038_s41588_018_0117_9 crossref_primary_10_1016_j_smim_2018_07_001 crossref_primary_10_1016_j_jconrel_2013_07_030 crossref_primary_10_3389_fimmu_2014_00361 crossref_primary_10_1016_S2213_2600_18_30077_8 crossref_primary_10_1371_journal_pntd_0007083 crossref_primary_10_3389_fmicb_2022_947852 crossref_primary_10_4061_2011_632705 crossref_primary_10_1128_CVI_00372_14 crossref_primary_10_1016_j_vaccine_2009_03_018 crossref_primary_10_1128_IAI_02145_14 crossref_primary_10_1016_j_jinf_2016_06_012 crossref_primary_10_1371_journal_pone_0122560 crossref_primary_10_1016_j_ejpb_2021_03_007 crossref_primary_10_1111_j_1365_2796_2010_02216_x crossref_primary_10_1016_j_micpath_2014_03_011 crossref_primary_10_1002_iub_1387 crossref_primary_10_1155_2011_497203 crossref_primary_10_1038_s41541_020_00278_0 crossref_primary_10_1016_j_vaccine_2015_10_115 crossref_primary_10_1128_CVI_05037_11 crossref_primary_10_4049_jimmunol_1102696 crossref_primary_10_18632_oncotarget_8771 crossref_primary_10_4049_jimmunol_1401103 crossref_primary_10_1038_nri3694 crossref_primary_10_1093_infdis_jis421 crossref_primary_10_1093_infdis_jis425 crossref_primary_10_1021_pr301017e crossref_primary_10_1111_imr_13335 crossref_primary_10_1093_infdis_jis429 crossref_primary_10_1016_j_ebiom_2017_07_005 crossref_primary_10_1186_s12934_015_0385_3 crossref_primary_10_1038_s41467_020_16877_3 crossref_primary_10_1016_j_vaccine_2015_10_124 crossref_primary_10_1074_jbc_RA118_001696 crossref_primary_10_1128_CVI_05260_11 crossref_primary_10_3389_fimmu_2023_1307429 crossref_primary_10_1371_journal_pone_0022889 crossref_primary_10_2217_fmb_10_168 crossref_primary_10_3390_ijms24097928 crossref_primary_10_1038_s41591_022_02110_9 crossref_primary_10_3389_fcimb_2017_00068 crossref_primary_10_3389_fimmu_2023_1206529 crossref_primary_10_1016_j_compbiomed_2023_107155 crossref_primary_10_1016_j_ijid_2023_03_035 crossref_primary_10_1080_21691401_2018_1557674 crossref_primary_10_12688_aasopenres_13196_1 crossref_primary_10_1089_hgtb_2018_211 crossref_primary_10_1128_mBio_00226_21 crossref_primary_10_1016_j_vaccine_2023_10_026 crossref_primary_10_12688_aasopenres_13196_2 crossref_primary_10_12688_aasopenres_13196_3 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.4049/jimmunol.181.11.7948 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1550-6606 |
| EndPage | 7957 |
| ExternalDocumentID | PMC2586986 19017986 10_4049_jimmunol_181_11_7948 www181_11_7948 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: N01 AI040091 – fundername: NIAID NIH HHS grantid: R01 AI044373 – fundername: NIAID NIH HHS grantid: UC1 AI067251 – fundername: NIAID NIH HHS grantid: AI-067251 – fundername: NIAID NIH HHS grantid: AI-044373 |
| GroupedDBID | - 08R 2WC 34G 39C 3O- 53G 55 5GY 5RE 5VS 79B 85S 8RP AALRV AARDX ABEFU ABFLS ABOCM ABPPZ ABPTK ACGFS ACIWK ACNCT ACPRK ADACO ADBBV ADKFC AENEX AETEA AFFNX AFRAH AJYGW ALMA_UNASSIGNED_HOLDINGS BAWUL D0L DIK DU5 E3Z EBS EJD F5P FH7 FRP GX1 H13 IH2 K-O K78 KQ8 L7B MVM NEJ O0- OK1 P0W P2P PQEST PQQKQ R.V RHF RHI RZQ SJN TWZ WH7 WOQ X X7M XJT ZA5 ZE2 ZGI --- -~X .55 0R~ 18M 5WD AAYXX ABCQX ABDFA ABEJV ABGNP ABJNI ABXVV ACGFO ADIPN ADNWM ADXHL AFHIN AFOSN AGORE AHMMS AHWXS AIZAD ARBBW BCRHZ BTFSW CITATION OCZFY OWPYF ROX TR2 W8F XSW XTH YHG CGR CUY CVF ECM EIF NPM 7X8 KOP 5PM |
| ID | FETCH-LOGICAL-c426t-6fdc9598ed283881d9e543a6202902667bb6f55e0d01940a0b8ee36da1e613703 |
| ISSN | 0022-1767 1550-6606 |
| IngestDate | Thu Aug 21 18:17:11 EDT 2025 Fri Sep 05 12:40:37 EDT 2025 Fri May 30 10:59:44 EDT 2025 Thu Apr 24 23:10:50 EDT 2025 Tue Jul 01 05:13:14 EDT 2025 Tue Nov 10 19:22:50 EST 2020 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | https://academic.oup.com/pages/standard-publication-reuse-rights |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c426t-6fdc9598ed283881d9e543a6202902667bb6f55e0d01940a0b8ee36da1e613703 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 both authors contributed equally to the study |
| PMID | 19017986 |
| PQID | 69812457 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2586986 proquest_miscellaneous_69812457 pubmed_primary_19017986 crossref_citationtrail_10_4049_jimmunol_181_11_7948 crossref_primary_10_4049_jimmunol_181_11_7948 highwire_smallpub1_www181_11_7948 |
| ProviderPackageCode | RHF RHI CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-12-01 |
| PublicationDateYYYYMMDD | 2008-12-01 |
| PublicationDate_xml | – month: 12 year: 2008 text: 2008-12-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The Journal of immunology (1950) |
| PublicationTitleAlternate | J Immunol |
| PublicationYear | 2008 |
| Publisher | Am Assoc Immnol |
| Publisher_xml | – name: Am Assoc Immnol |
| References | (2025032719410272900_R19) 2008 (2025032719410272900_R30) 2000 (2025032719410272900_R42) 2006 (2025032719410272900_R29) 2005 (2025032719410272900_R40) 2003 (2025032719410272900_R37) 1999 (2025032719410272900_R12) 1998 (2025032719410272900_R6) 2001 (2025032719410272900_R17) 2005 (2025032719410272900_R22) 1999 (2025032719410272900_R27) 2005 2025032719410272900_R5 (2025032719410272900_R1) 2007 (2025032719410272900_R14) 2001 (2025032719410272900_R35) 1993 (2025032719410272900_R20) 2007 (2025032719410272900_R10) 2006 (2025032719410272900_R25) 2002 (2025032719410272900_R9) 2007 (2025032719410272900_R32) 2000 (2025032719410272900_R4) 2005 (2025032719410272900_R15) 2006 (2025032719410272900_R41) 2005 (2025032719410272900_R28) 2004 (2025032719410272900_R7) 2005 (2025032719410272900_R43) 2007 (2025032719410272900_R2) 2007 (2025032719410272900_R13) 2003 (2025032719410272900_R38) 2003 (2025032719410272900_R18) 2001 (2025032719410272900_R33) 2007 (2025032719410272900_R3) 2005 (2025032719410272900_R34) 2004 (2025032719410272900_R16) 2005 (2025032719410272900_R23) 2000 (2025032719410272900_R24) 2006 (2025032719410272900_R11) 2006 (2025032719410272900_R36) 1993 (2025032719410272900_R21) 2004 (2025032719410272900_R39) 2008 (2025032719410272900_R8) 2007 (2025032719410272900_R31) 2005 (2025032719410272900_R26) 2000 |
| References_xml | – start-page: 3110 volume-title: J. Immunol. year: 2003 ident: 2025032719410272900_R38 article-title: Reactivation of latent tuberculosis infection in TNF-deficient mice – start-page: 363 volume-title: Trans. R. Soc. Trop. Med. Hyg. year: 2005 ident: 2025032719410272900_R41 article-title: PPD induced in vitro interferon γproduction is not a reliable correlate of protection against Mycobacterium tuberculosis – start-page: 2249 volume-title: J. Exp. Med. year: 1993 ident: 2025032719410272900_R36 article-title: An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection – volume-title: Global Tuberculosis Control: Surveilance, Planning, Financing year: 2007 ident: 2025032719410272900_R1 – start-page: 7140 volume-title: J. Immunol. year: 2000 ident: 2025032719410272900_R23 article-title: T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection – start-page: 911 volume-title: Microbes Infect. year: 2005 ident: 2025032719410272900_R7 article-title: TB subunit vaccines: putting the pieces together – ident: 2025032719410272900_R5 – start-page: 7168 volume-title: Vaccine year: 2007 ident: 2025032719410272900_R20 article-title: Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant – start-page: 843 volume-title: Nat. Med. year: 2007 ident: 2025032719410272900_R43 article-title: Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major – start-page: 3849 volume-title: Proc. Natl. Acad. Sci. USA year: 2008 ident: 2025032719410272900_R19 article-title: Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen – start-page: 5479 volume-title: J. Bacteriol. year: 2002 ident: 2025032719410272900_R25 article-title: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains – start-page: 53 volume-title: Vet. Immunol. Immunopathol. year: 2005 ident: 2025032719410272900_R31 article-title: Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis – start-page: 4689 volume-title: J. Immunol. year: 2003 ident: 2025032719410272900_R40 article-title: CD4+ T cells mediate IFN-γ-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo – start-page: 2128 volume-title: Infect. Immun. year: 2006 ident: 2025032719410272900_R42 article-title: An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis – start-page: 6332 volume-title: J. Immunol. year: 2005 ident: 2025032719410272900_R27 article-title: Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy – start-page: 6340 volume-title: Vaccine year: 2006 ident: 2025032719410272900_R24 article-title: Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge – start-page: 537 volume-title: Nature year: 1998 ident: 2025032719410272900_R12 article-title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence – start-page: 2941 volume-title: Infect. Immun. year: 1999 ident: 2025032719410272900_R22 article-title: Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family – start-page: 656 volume-title: Nat. Rev. Microbiol. year: 2005 ident: 2025032719410272900_R3 article-title: The success and failure of BCG: implications for a novel tuberculosis vaccine – start-page: 7534 volume-title: Proc. Natl. Acad. Sci. USA year: 2001 ident: 2025032719410272900_R14 article-title: Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin – start-page: 484 volume-title: Nat. Rev. Microbiol. year: 2007 ident: 2025032719410272900_R9 article-title: Tuberculosis vaccines: an update – start-page: 1237 volume-title: J. Infect. Dis. year: 2004 ident: 2025032719410272900_R21 article-title: Regions of high antigenicity within the hypothetical PPE major polymorphic tandem repeat open-reading frame, Rv2608, show a differential humoral response and a low T cell response in various categories of patients with tuberculosis – start-page: 7618 volume-title: J. Immunol. year: 2004 ident: 2025032719410272900_R34 article-title: Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein – start-page: 2030 volume-title: Lancet year: 2007 ident: 2025032719410272900_R2 article-title: Tuberculosis – start-page: 12989 volume-title: Proc. Natl. Acad. Sci. USA year: 2003 ident: 2025032719410272900_R13 article-title: Genetic requirements for mycobacterial survival during infection – start-page: 1724 volume-title: Eur. J. Immunol. year: 2000 ident: 2025032719410272900_R30 article-title: Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen – start-page: 1068 volume-title: Int. J. Tuberc. Lung Dis. year: 2006 ident: 2025032719410272900_R10 article-title: Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis – start-page: 687 volume-title: Clin. Microbiol. Rev. year: 2005 ident: 2025032719410272900_R4 article-title: Vaccines for tuberculosis: novel concepts and recent progress – start-page: 173 volume-title: Clin. Immunol. year: 2007 ident: 2025032719410272900_R33 article-title: Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice – start-page: 922 volume-title: Microbes Infect. year: 2005 ident: 2025032719410272900_R17 article-title: Tuberculosis vaccine development; from mouse to man – start-page: 791 volume-title: Infect. Immun. year: 2000 ident: 2025032719410272900_R26 article-title: ESAT-6 subunit vaccination against Mycobacterium tuberculosis – start-page: 139 volume-title: Clin. Exp. Immunol. year: 2004 ident: 2025032719410272900_R28 article-title: In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis – start-page: 2948 volume-title: Infect. Immun. year: 2000 ident: 2025032719410272900_R32 article-title: CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis – start-page: 93 volume-title: Annu. Rev. Immunol. year: 2001 ident: 2025032719410272900_R6 article-title: Immunology of tuberculosis – start-page: 469 volume-title: Nat. Rev. Microbiol. year: 2006 ident: 2025032719410272900_R15 article-title: Advances in tuberculosis vaccine strategies – start-page: 244 volume-title: Trends Parasitol. year: 2005 ident: 2025032719410272900_R16 article-title: Second-generation vaccines against leishmaniasis – start-page: 2557 volume-title: Vaccine year: 2005 ident: 2025032719410272900_R29 article-title: Protective immunity against Mycobacterium bovis induced by vaccination with Rv3109c: a member of the esat-6 gene family – start-page: 2243 volume-title: J. Exp. Med. year: 1993 ident: 2025032719410272900_R35 article-title: Disseminated tuberculosis in interferon gamma gene-disrupted mice – start-page: 3504 volume-title: J. Immunol. year: 1999 ident: 2025032719410272900_R37 article-title: Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin – start-page: 239 volume-title: Clin. Immunol. year: 2007 ident: 2025032719410272900_R8 article-title: Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity – start-page: 135 volume-title: Int. Rev. Immunol. year: 2006 ident: 2025032719410272900_R11 article-title: Adjuvant activity of CpG oligodeoxynucleotides – start-page: 2773 volume-title: Infect. Immun. year: 2001 ident: 2025032719410272900_R18 article-title: Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6 – start-page: 183 volume-title: Clin. Microbiol. Infect. year: 2008 ident: 2025032719410272900_R39 article-title: Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment |
| SSID | ssj0006024 |
| Score | 2.3514752 |
| Snippet | Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using... Development of a subunit vaccine for Mycobacterium tuberculosis ( Mtb ) depends on the identification of antigens that induce appropriate T cell responses.... |
| SourceID | pubmedcentral proquest pubmed crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 7948 |
| SubjectTerms | Adjuvants, Immunologic - genetics Adjuvants, Immunologic - pharmacology Animals Antibodies, Bacterial - immunology Antigens, Bacterial - genetics Antigens, Bacterial - immunology Antigens, Bacterial - pharmacology CD8-Positive T-Lymphocytes - immunology Computational Biology Disease Models, Animal Female Humans Immunoglobulin G - immunology Interferon-gamma - immunology Mice Mycobacterium bovis - immunology Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - immunology Oligodeoxyribonucleotides - genetics Oligodeoxyribonucleotides - immunology Oligodeoxyribonucleotides - pharmacology Recombinant Proteins - genetics Recombinant Proteins - immunology Recombinant Proteins - pharmacology Th1 Cells - immunology Tuberculosis Vaccines - genetics Tuberculosis Vaccines - immunology Tuberculosis Vaccines - pharmacology Tuberculosis, Pulmonary - genetics Tuberculosis, Pulmonary - immunology Tuberculosis, Pulmonary - prevention & control Tumor Necrosis Factor-alpha - immunology |
| Title | Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis |
| URI | http://www.jimmunol.org/cgi/content/abstract/181/11/7948 https://www.ncbi.nlm.nih.gov/pubmed/19017986 https://www.proquest.com/docview/69812457 https://pubmed.ncbi.nlm.nih.gov/PMC2586986 |
| Volume | 181 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEGgvCMZl5WokeKpScnWTR0AbG1vHA6nUN8txHFaUpahJVpVHfjnnJE6aoEoDXqLKdePU3xefi885JuQN89REuqasMpYNFxQEI4qEMOBNci0ZCOHFmCg8vWAnM_fz3JsPBr86UUtlEY3lz515Jf-DKrQBrpgl-w_ItjeFBvgM-MIVEIbrX2FcZ9km2u1W6X2VTz4coT9-BJOGtTbzNpQw3kYIYedrIXFbPR-Jb2IBauJoupHwelflm8urUVFGaiXLdJkv8q4Ou80mqwtOYIZJXcnpbbVfZna8Cx_UCv2u9Y7H1016vWiJdLpSOnRf58lsHbZn4jLTiUSLVmx8KmOc06yTf9ZzWfid8A-9ynpgszJT18De0dYuzVaXg1ZnpYV1xN8lAlwweVAE6D8_hluAWBg33fsVty--8OPZ-TkPj-bhLXLbnoD-hYr16VkrzZlZH4zcPF6dfomjvNs1Rl-9aUpO7zJf_ozC7ag14X1yT-NI39fkekAGKjsgd-oTSjcH5O5Ux148JN_7bKPLhFZsoyFFttGGbRTYRoFttMM27NywjWq20R7baJdtj8js-Cj8eGLokzoMCRpeYbAkloEX-CoGbdUHEyhQnusIZpt2AEY-m0QRSzxPmTFYFK4pzMhXymGxsBSokyB0HpO9bJmpQ0IlKNhxYCszSSLcwxdWpPwkYEoGjsOcyZA4zQRzqcvY42kqKQdzFmHhDSwcYAEDlyMsQ2K0v_pRl3G5of_rBjueX4k0Bagsvl6ve31eNaByWJNxqkWmlmXOWYBqswfP-qSGeDtmgBLQZ0My6YHfdsBq7_1vssVlVfXd9ny4L3t646jPyP72pXtO9opVqV6A5lxELytq_wZpl8qf |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+human+T+cell+antigens+for+the+development+of+vaccines+against+Mycobacterium+tuberculosis&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Bertholet%2C+Sylvie&rft.au=Ireton%2C+Gregory+C&rft.au=Kahn%2C+Maria&rft.au=Guderian%2C+Jeffrey&rft.date=2008-12-01&rft.issn=1550-6606&rft.eissn=1550-6606&rft.volume=181&rft.issue=11&rft.spage=7948&rft_id=info:doi/10.4049%2Fjimmunol.181.11.7948&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon |